{"Title": "RATIONALE 301 study: Tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma", "Year": 2019, "Source": "Future Oncol.", "Volume": "15", "Issue": 16, "Art.No": null, "PageStart": 1811, "PageEnd": 1822, "CitedBy": 21, "DOI": "10.2217/fon-2019-0097", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85067336594&origin=inward", "Abstract": "\u00a9 2019 2019 Shukui Qin.Advanced, unresectable hepatocellular carcinoma (HCC) has a poor prognosis with median life expectancy of approximately 1 year. Overexpression of PD-L1 in tumor cells and PD-1 on tumor-infiltrating T cells has been associated with poorer prognosis, more advanced disease and higher recurrence rates in HCC. Monoclonal antibodies against PD-1 have demonstrated antitumor activity in patients with solid tumors, including HCC. Tislelizumab, an investigational, humanized IgG4 monoclonal antibody with high affinity and binding specificity for PD-1, has demonstrated preliminary antitumor activity in HCC. Here we describe a head-To-head Phase III study comparing the efficacy, safety and tolerability of tislelizumab with sorafenib as first-line treatment in unresectable HCC.", "AuthorKeywords": ["HCC", "hepatocellular carcinoma", "PD-1", "tislelizumab"], "IndexKeywords": ["Adult", "Aged", "Antineoplastic Agents, Immunological", "B7-H1 Antigen", "Carcinoma, Hepatocellular", "Female", "Humans", "Induction Chemotherapy", "Liver Neoplasms", "Male", "Middle Aged", "Neoplasm Metastasis", "Neoplasm Staging", "Protein Kinase Inhibitors", "Sorafenib", "Treatment Outcome"], "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 1, "EID": "2-s2.0-85067336594", "SubjectAreas": [["Oncology", "MEDI", "2730"], ["Cancer Research", "BIOC", "1306"]], "AuthorData": {"55984746100": {"Name": "Qin S.", "AuthorID": "55984746100", "AffiliationID": "113030530", "AffiliationName": "People's Liberation Army (PLA) 81 Hospital"}, "35181198600": {"Name": "Finn R.S.", "AuthorID": "35181198600", "AffiliationID": "60027550", "AffiliationName": "University of California Los Angeles"}, "55216757300": {"Name": "Kudo M.", "AuthorID": "55216757300", "AffiliationID": "60031607", "AffiliationName": "Department of Gastroenterology and Hepatology, Kindai University School of Medicine"}, "57199899475": {"Name": "Meyer T.", "AuthorID": "57199899475", "AffiliationID": "60022148", "AffiliationName": "University College London Cancer Institute"}, "7102618692": {"Name": "Vogel A.", "AuthorID": "7102618692", "AffiliationID": "60024052", "AffiliationName": "Medizinische Hochschule Hannover"}, "7102361215": {"Name": "Ducreux M.", "AuthorID": "7102361215", "AffiliationID": "60106080", "AffiliationName": "Gustave Roussy"}, "8702260000": {"Name": "Macarulla T.M.", "AuthorID": "8702260000", "AffiliationID": "60110094, 60012486", "AffiliationName": "Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital"}, "23994463400": {"Name": "Tomasello G.", "AuthorID": "23994463400", "AffiliationID": "60086768", "AffiliationName": "Azienda Istituti Ospitalieri di Cremona"}, "7801411218": {"Name": "Boisserie F.", "AuthorID": "7801411218", "AffiliationID": "60119191", "AffiliationName": "BeiGene, Inc"}, "57209316892": {"Name": "Hou J.", "AuthorID": "57209316892", "AffiliationID": "60119191", "AffiliationName": "BeiGene, Inc"}, "57209323217": {"Name": "Song J.", "AuthorID": "57209323217", "AffiliationID": "60119191", "AffiliationName": "BeiGene, Inc"}, "57209323559": {"Name": "Li X.", "AuthorID": "57209323559", "AffiliationID": "60119191", "AffiliationName": "BeiGene Co., Ltd"}, "7102514556": {"Name": "Zhu A.X.", "AuthorID": "7102514556", "AffiliationID": "60008130, 60002746", "AffiliationName": "Harvard Medical School, Massachusetts General Hospital Cancer Center"}}}